SLRN

Insider Trades

Name	Value	Action	Price	Current Price
Becker Daniel J.Director $71 shares SellJul 17, 2024 $6.86 --
Mpofu ShephardChief Medical Officer $8.8k3.2k shares SellMar 17, 2025 $2.74 --
Murugan AmarChief Legal Officer $11k3.9k shares SellMar 17, 2025 $2.74 --
Kim MinaDirector, Officer: Chief Executive Officer $49k18k shares SellMar 17, 2025 $2.74 --

Trade SLRN

About Acelyrin, Inc.

Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.

CEO: Mina Kim
IPO Date: May 4, 2023

Market Data

Open: $2.27
High: $2.27
Low: $2.27
Volume: 4.1M
Avg Volume: 997K
52W High: $7.25
52W Low: $1.85

Valuation

Market Cap: $229M
Enterprise Value: $177M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-305M
Revenue: $0
Net Income: $-248M
Cash: $74M
Debt: $6.3M

Events

EarningsNov 11